{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T22:33:22Z","timestamp":1781130802873,"version":"3.54.1"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004726","name":"Italian Ministry of Health","doi-asserted-by":"publisher","award":["RF-2011-02348358"],"award-info":[{"award-number":["RF-2011-02348358"]}],"id":[{"id":"10.13039\/501100004726","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.coph.2016.01.010","type":"journal-article","created":{"date-parts":[[2016,2,16]],"date-time":"2016-02-16T15:45:40Z","timestamp":1455637540000},"page":"56-61","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Novel biomarkers and therapies in cardiorenal syndrome"],"prefix":"10.1016","volume":"27","author":[{"given":"Roberto","family":"Latini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aneta","family":"Aleksova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Masson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2016.01.010_sbref0005","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/j.jacc.2008.07.051","article-title":"Cardiorenal syndrome","volume":"52","author":"Ronco","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.coph.2016.01.010_bib0010","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.jacc.2013.11.031","article-title":"Current evidence on treatment of patients with chronic systolic heart failure and renal insufficiency: practical considerations from published data","volume":"63","author":"Damman","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.coph.2016.01.010_sbref0015","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1093\/eurheartj\/ehs205","article-title":"The role of the kidney in heart failure","volume":"33","author":"Metra","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.coph.2016.01.010_bib0020","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1001\/jama.293.5.572","article-title":"Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis","volume":"293","author":"Fonarow","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.coph.2016.01.010_bib0025","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1161\/01.CIR.102.2.203","article-title":"Renal function, neurohormonal activation, and survival in patients with chronic heart failure","volume":"102","author":"Hillege","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.coph.2016.01.010_bib0030","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1161\/CIRCHEARTFAILURE.112.967828","article-title":"Predictors of mortality in 6975 patients with chronic heart failure in the Gruppo Italiano per lo Studio della Streptochinasi nell\u2019Infarto Miocardico-Heart Failure trial: proposal for a nomogram","volume":"6","author":"Barlera","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.coph.2016.01.010_bib0035","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s00134-008-1017-8","article-title":"Cardiorenal syndrome: refining the definition of a complex symbiosis gone wrong","volume":"34","author":"Ronco","year":"2008","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.coph.2016.01.010_bib0040","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.2215\/CJN.03150509","article-title":"Cardiorenal syndrome in acute decompensated heart failure","volume":"4","author":"Sarraf","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.coph.2016.01.010_bib0045","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1056\/NEJMoa1005419","article-title":"Diuretic strategies in patients with acute decompensated heart failure","volume":"364","author":"Felker","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2016.01.010_bib0050","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jcrc.2013.10.009","article-title":"Loop diuretic strategies in patients with acute decompensated heart failure: a meta-analysis of randomized controlled trials","volume":"29","author":"Wu","year":"2014","journal-title":"J Crit Care"},{"key":"10.1016\/j.coph.2016.01.010_sbref0055","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.cardfail.2015.07.007","article-title":"Intensification of medication therapy for cardiorenal syndrome in acute decompensated heart failure","volume":"22","author":"Grodin","year":"2016","journal-title":"J Card Fail"},{"key":"10.1016\/j.coph.2016.01.010_bib0060","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.cardfail.2010.02.001","article-title":"The relationship between transient and persistent worsening renal function and mortality in patients with acute decompensated heart failure","volume":"16","author":"Aronson","year":"2010","journal-title":"J Card Fail"},{"key":"10.1016\/j.coph.2016.01.010_bib0065","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.ejheart.2007.07.011","article-title":"Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE Trial","volume":"9","author":"Hasselblad","year":"2007","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.coph.2016.01.010_bib0070","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1159\/000164149","article-title":"Impact of intravenous loop diuretics on outcomes of patients hospitalized with acute decompensated heart failure: insights from the ADHERE registry","volume":"113","author":"Peacock","year":"2009","journal-title":"Cardiology"},{"key":"10.1016\/j.coph.2016.01.010_bib0075","doi-asserted-by":"crossref","first-page":"e240","DOI":"10.1161\/CIR.0b013e31829e8776","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines","volume":"128","author":"WRITING COMMITTEE MEMBERS","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.coph.2016.01.010_bib0080","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1056\/NEJMoa1210357","article-title":"Ultrafiltration in decompensated heart failure with cardiorenal syndrome","volume":"367","author":"Bart","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2016.01.010_bib0085","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1096\/fj.13-233429","article-title":"Localization of relaxin receptors in arteries and veins, and region specific increases in compliance and bradykinin-mediated relaxation after in vivo serelaxin treatment","volume":"28","author":"Jelinic","year":"2014","journal-title":"FASEB J"},{"key":"10.1016\/j.coph.2016.01.010_bib0090","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(12)61855-8","article-title":"Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial","volume":"381","author":"Teerlink","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2016.01.010_sbref0095","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jacc.2012.11.005","article-title":"Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes","volume":"61","author":"Metra","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.coph.2016.01.010_bib0100","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1001\/jama.2013.282190","article-title":"Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial","volume":"310","author":"Chen","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.coph.2016.01.010_bib0105","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.cardfail.2010.07.246","article-title":"Impact of dopamine infusion on renal function in hospitalized heart failure patients: results of the Dopamine in Acute Decompensated Heart Failure (DAD-HF) Trial","volume":"16","author":"Giamouzis","year":"2010","journal-title":"J Card Fail"},{"key":"10.1016\/j.coph.2016.01.010_bib0110","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S0140-6736(02)09455-2","article-title":"Efficacy and safety of intravenous levosimendan compared with dobutamina in severe low-output heart failure (the LIDO study): a randomized double-blind trial","volume":"360","author":"Follath","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2016.01.010_sbref0115","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/ejhf.9","article-title":"Levosimendan improves renal function in acute decompensated heart failure: possible underlying mechanisms","volume":"16","author":"Fedele","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.coph.2016.01.010_bib0120","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJM199209033271001","article-title":"Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators","volume":"327","author":"Pfeffer","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2016.01.010_bib0125","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1053\/euhj.1998.1098","article-title":"Long-term survival in severe heart failure in patients treated with enalapril. Ten year follow-up of CONSENSUS I","volume":"20","author":"Swedberg","year":"1999","journal-title":"Eur Heart J"},{"key":"10.1016\/j.coph.2016.01.010_bib0130","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1056\/NEJM199604113341502","article-title":"Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency: the Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Disease trial","volume":"334","author":"Maschio","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2016.01.010_bib0135","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S0272-6386(96)90158-4","article-title":"Angiotensin-converting enzyme inhibition in non-diabetic progressive renal insufficiency: a controlled double-blinded trial","volume":"27","author":"Ihle","year":"1996","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.coph.2016.01.010_bib0140","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/0002-9149(92)91194-9","article-title":"Renal function in severe congestive heart failure during treatment with enalapril (the Cooperative North Scandinavian Enalapril Survival Study [CONSENSUS] Trial)","volume":"70","author":"Ljungman","year":"1992","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.coph.2016.01.010_bib0145","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1093\/eurheartj\/ehr238","article-title":"Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial","volume":"32","author":"Blair","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.coph.2016.01.010_bib0150","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2016.01.010_sbref0155","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1093\/eurjhf\/hft110","article-title":"Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial","volume":"15","author":"Greene","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.coph.2016.01.010_bib0160","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1161\/CIRCHEARTFAILURE.113.000284","volume":"7","author":"Cleland","year":"2014","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.coph.2016.01.010_bib0165","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1093\/eurheartj\/ehu320","article-title":"Terminology and definition of changes renal function in heart failure","volume":"35","author":"Damman","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.coph.2016.01.010_bib0170","doi-asserted-by":"crossref","first-page":"e112313","DOI":"10.1371\/journal.pone.0112313","article-title":"Evidence of uncoupling between renal dysfunction and injury in cardiorenal syndrome: insights from the BIONICS study","volume":"9","author":"Legrand","year":"2014","journal-title":"PLOS ONE"},{"key":"10.1016\/j.coph.2016.01.010_sbref0175","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1097\/CCM.0000000000000404","article-title":"When cardiac failure, kidney dysfunction, and kidney injury intersect in acute conditions: the case of cardiorenal syndrome","volume":"42","author":"Legrand","year":"2014","journal-title":"Crit Care Med"},{"key":"10.1016\/j.coph.2016.01.010_sbref0180","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0140-6736(09)61378-7","article-title":"Albuminuria in chronic heart failure: prevalence and prognostic importance","volume":"374","author":"Jackson","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2016.01.010_sbref0185","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1161\/CIRCHEARTFAILURE.109.881805","article-title":"Prevalence and prognostic value of elevated urinary albumin excretion in patients with chronic heart failure: data from the GISSI-Heart Failure trial","volume":"3","author":"Masson","year":"2010","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.coph.2016.01.010_bib0190","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1093\/eurheartj\/ehr190","article-title":"Clinical outcome of renal tubular damage in chronic heart failure","volume":"32","author":"Damman","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.coph.2016.01.010_sbref0195","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.jchf.2013.05.007","article-title":"Tubular damage and worsening renal function in chronic heart failure","volume":"1","author":"Damman","year":"2013","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.coph.2016.01.010_sbref0200","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1172\/JCI46122","article-title":"FGF23 induces left ventricular hypertrophy","volume":"121","author":"Faul","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coph.2016.01.010_bib0205","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1001\/jama.2011.826","article-title":"Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease","volume":"305","author":"Isakova","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.coph.2016.01.010_bib0210","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.2215\/CJN.01880213","article-title":"Fibroblast growth factor 23 and cardiovascular mortality after kidney transplantation","volume":"8","author":"Baia","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.coph.2016.01.010_bib0215","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/joim.12232","article-title":"The fibroblast growth factor-23 and Vitamin D emerge as nontraditional risk factors and may affect cardiovascular risk","volume":"277","author":"Masson","year":"2015","journal-title":"J Intern Med"},{"key":"10.1016\/j.coph.2016.01.010_bib0220","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1016\/j.jacc.2014.03.026","article-title":"Fibroblast growth factor-23, cardiovascular prognosis, and benefit of angiotensin-converting enzyme inhibition in stable ischemic heart disease","volume":"63","author":"Udell","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.coph.2016.01.010_sbref0225","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1161\/CIRCULATIONAHA.111.032680","article-title":"Cardiomyocyte-specific deletion of the vitamin D receptor gene results in cardiac hypertrophy","volume":"124","author":"Chen","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.coph.2016.01.010_bib0230","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1093\/eurheartj\/eht166","article-title":"Vitamin D and cardiovascular disease: is the evidence solid?","volume":"34","author":"Al Mheid","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.coph.2016.01.010_bib0235","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/ndt\/gfv130","article-title":"Cell-cycle arrest and acute kidney injury: the light and the dark sides","volume":"31","author":"Kellum","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.coph.2016.01.010_sbref0240","doi-asserted-by":"crossref","first-page":"R25","DOI":"10.1186\/cc12503","article-title":"Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury","volume":"17","author":"Kashani","year":"2013","journal-title":"Crit Care"},{"key":"10.1016\/j.coph.2016.01.010_bib0245","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/j.amjcard.2014.08.018","article-title":"Prognostic usefulness of insulin-like growth factor-binding protein 7 in heart failure with reduced ejection fraction: a novel biomarker of myocardial diastolic function?","volume":"114","author":"Gandhi","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.coph.2016.01.010_sbref0250","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1164\/rccm.201401-0077OC","article-title":"Validation of cell-cycle arrest biomarkers for acute kidney injury using clinical adjudication","volume":"189","author":"Bihorac","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.coph.2016.01.010_sbref0255","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1093\/ndt\/gfu292","article-title":"Derivation and validation of cutoffs for clinical use of cell cycle arrest biomarkers","volume":"29","author":"Hoste","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.coph.2016.01.010_bib0260","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1681\/ASN.2014060556","article-title":"Tissue inhibitor metalloproteinase-2 (TIMP-2)(IGF-binding protein-7 (IGFBP7) levels are associated with adverse long-term outcomes in patients with AKI","volume":"26","author":"Koyner","year":"2015","journal-title":"J Am Soc Nephrol"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489216300066?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489216300066?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,15]],"date-time":"2018-09-15T00:56:35Z","timestamp":1536972995000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489216300066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":52,"alternative-id":["S1471489216300066"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2016.01.010","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel biomarkers and therapies in cardiorenal syndrome","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2016.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}